Hoth Therapeutics | 8-K: Current report
Hoth Therapeutics | 8-K: Current report
Hoth Therapeutics | 10-Q: Q3 2024 Earnings Report
Hoth Therapeutics | 424B5: Prospectus
Hoth Therapeutics | 8-K: Current report
Hoth Therapeutics | 8-K: Current report
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Pavell Jeff
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sarnoff David
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Knie Robb
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Linsley Wayne
Hoth Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Knie Robb
Hoth Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Hoth Therapeutics | 10-Q: Q2 2024 Earnings Report
Hoth Therapeutics | 8-K: Current report
Hoth Therapeutics | ARS: Annual Report to Security Holders
Hoth Therapeutics | DEFA14A: Others
Hoth Therapeutics | DEF 14A: Definitive information statements
Hoth Therapeutics | 8-K: Current report
Hoth Therapeutics | 10-Q: Q1 2024 Earnings Report
Hoth Therapeutics | 424B3: Prospectus